285 related articles for article (PubMed ID: 10084362)
1. Molecular chemotherapy for breast cancer.
Patterson A; Harris AL
Drugs Aging; 1999 Feb; 14(2):75-90. PubMed ID: 10084362
[TBL] [Abstract][Full Text] [Related]
2. Targeting gene therapy to cancer: a review.
Dachs GU; Dougherty GJ; Stratford IJ; Chaplin DJ
Oncol Res; 1997; 9(6-7):313-25. PubMed ID: 9406237
[TBL] [Abstract][Full Text] [Related]
3. Genetic prodrug activation therapy for breast cancer: A phase I clinical trial of erbB-2-directed suicide gene expression.
Pandha HS; Martin LA; Rigg A; Hurst HC; Stamp GW; Sikora K; Lemoine NR
J Clin Oncol; 1999 Jul; 17(7):2180-9. PubMed ID: 10561274
[TBL] [Abstract][Full Text] [Related]
4. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.
Roy P; Waxman DJ
Toxicol In Vitro; 2006 Mar; 20(2):176-86. PubMed ID: 16293390
[TBL] [Abstract][Full Text] [Related]
5. In vitro evaluation of cancer-specific NF-kappaB-CEA enhancer-promoter system for 5-fluorouracil prodrug gene therapy in colon cancer cell lines.
Guo X; Evans TR; Somanath S; Armesilla AL; Darling JL; Schatzlein A; Cassidy J; Wang W
Br J Cancer; 2007 Sep; 97(6):745-54. PubMed ID: 17687334
[TBL] [Abstract][Full Text] [Related]
6. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene.
Chen L; Waxman DJ; Chen D; Kufe DW
Cancer Res; 1996 Mar; 56(6):1331-40. PubMed ID: 8640822
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia-mediated tumour targeting.
Binley K; Askham Z; Martin L; Spearman H; Day D; Kingsman S; Naylor S
Gene Ther; 2003 Apr; 10(7):540-9. PubMed ID: 12646859
[TBL] [Abstract][Full Text] [Related]
8. Prodrug activation enzymes in cancer gene therapy.
Aghi M; Hochberg F; Breakefield XO
J Gene Med; 2000; 2(3):148-64. PubMed ID: 10894261
[TBL] [Abstract][Full Text] [Related]
9. Thymidine kinase/ganciclovir and cytosine deaminase/5-fluorocytosine suicide gene therapy-induced cell apoptosis in breast cancer cells.
Kong H; Tao L; Qi K; Wang Y; Li Q; Du J; Huang Z
Oncol Rep; 2013 Sep; 30(3):1209-14. PubMed ID: 23799574
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon.
Akbulut H; Zhang L; Tang Y; Deisseroth A
Cancer Gene Ther; 2003 May; 10(5):388-95. PubMed ID: 12719708
[TBL] [Abstract][Full Text] [Related]
11. Development of a hypoxia-inducible cytosine deaminase expression vector for gene-directed prodrug cancer therapy.
Wang D; Ruan H; Hu L; Lamborn KR; Kong EL; Rehemtulla A; Deen DF
Cancer Gene Ther; 2005 Mar; 12(3):276-83. PubMed ID: 15650767
[TBL] [Abstract][Full Text] [Related]
12. Eradication of breast cancer xenografts by hyperthermic suicide gene therapy under the control of the heat shock protein promoter.
Braiden V; Ohtsuru A; Kawashita Y; Miki F; Sawada T; Ito M; Cao Y; Kaneda Y; Koji T; Yamashita S
Hum Gene Ther; 2000 Dec; 11(18):2453-63. PubMed ID: 11119417
[TBL] [Abstract][Full Text] [Related]
13. Bystander effects of different enzyme-prodrug systems for cancer gene therapy depend on different pathways for intercellular transfer of toxic metabolites, a factor that will govern clinical choice of appropriate regimes.
Denning C; Pitts JD
Hum Gene Ther; 1997 Oct; 8(15):1825-35. PubMed ID: 9358032
[TBL] [Abstract][Full Text] [Related]
14. Radiogenic therapy: novel approaches for enhancing tumor radiosensitivity.
Robson T; Worthington J; McKeown SR; Hirst DG
Technol Cancer Res Treat; 2005 Aug; 4(4):343-61. PubMed ID: 16029055
[TBL] [Abstract][Full Text] [Related]
15. Vector targeting makes 5-fluorouracil chemotherapy less toxic and more effective in animal models of epithelial neoplasms.
Akbulut H; Tang Y; Maynard J; Zhang L; Pizzorno G; Deisseroth A
Clin Cancer Res; 2004 Nov; 10(22):7738-46. PubMed ID: 15570008
[TBL] [Abstract][Full Text] [Related]
16. Targeted prodrug approaches for hormone refractory prostate cancer.
Aloysius H; Hu L
Med Res Rev; 2015 May; 35(3):554-85. PubMed ID: 25529338
[TBL] [Abstract][Full Text] [Related]
17. The role of cellular- and prodrug-associated factors in the bystander effect induced by the Varicella zoster and Herpes simplex viral thymidine kinases in suicide gene therapy.
Grignet-Debrus C; Cool V; Baudson N; Velu T; Calberg-Bacq CM
Cancer Gene Ther; 2000 Nov; 7(11):1456-68. PubMed ID: 11129288
[TBL] [Abstract][Full Text] [Related]
18. Dual-therapeutic reporter genes fusion for enhanced cancer gene therapy and imaging.
Sekar TV; Foygel K; Willmann JK; Paulmurugan R
Gene Ther; 2013 May; 20(5):529-37. PubMed ID: 22914496
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma.
Braybrooke JP; Slade A; Deplanque G; Harrop R; Madhusudan S; Forster MD; Gibson R; Makris A; Talbot DC; Steiner J; White L; Kan O; Naylor S; Carroll MW; Kingsman SM; Harris AL
Clin Cancer Res; 2005 Feb; 11(4):1512-20. PubMed ID: 15746054
[TBL] [Abstract][Full Text] [Related]
20. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer.
Connors TA
Gene Ther; 1995 Dec; 2(10):702-9. PubMed ID: 8750009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
